<DOC>
	<DOCNO>NCT00454883</DOCNO>
	<brief_summary>Assessment ziprasidone safety efficacy treatment bipolar schizoaffective disorder .</brief_summary>
	<brief_title>Non-interventional Study Ziprasidone Treatment Bipolar Schizoaffective Disorders .</brief_title>
	<detailed_description>Method : Consecutive patient sample . Patients include study consecutive manner fulfil inclusion criterion exclusion criterion present .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Affective Disorders , Psychotic</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Manic mixed episode moderate severity patient Type I II bipolar disorder schizoaffective disorder ; either first diagnose repeat episode Hypersensitivity ziprasidone prolong QTc interval coadministration substance prolong QTc interval recent acute MI , cardiac failure , patient arrhythmias treated class IA III medicament</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Safety ziprasidone , efficacy ziprasidone , manic episode bipolar disorder , mixed episode bipolar disorder , schizoaffective disorder .</keyword>
</DOC>